Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
NCT03985046Phase 2Completed
- Sponsor
- Fudan University
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fudan University. Primary endpoint: Local Control Rate at 42 months. Started Oct 2019; status: completed.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03985046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985046.